Sign up USA
Proactive Investors - Run By Investors For Investors

Kura Oncology shares double after successful results from phase II trial of lead candidate

Kura revealed late on Thursday that its tipifarnib head and neck cancer (NNSCC) candidate had achieved its primary endpoint before enrolment had even finished
cancer cells under a microscope
Head and neck cancer is one of the leading causes of cancer-related deaths worldwide

The market value of Kura Oncology Inc (NASDAQ:KURA) almost doubled on Friday morning after the biopharma announced positive results from phase II study of its lead cancer treatment.

Kura revealed late on Thursday that its tipifarnib head and neck cancer (NNSCC) candidate had achieved its primary endpoint before enrolment had even finished.

To be considered a success, the trial needed four confirmed partial responses to meet achieve the endpoint.

From the first six patients alone, four had confirmed partial responses while two others had disease stabilisation.

“We have observed rapid and, in some cases, dramatic responses in patients with relapsed and/or refractory HNSCC who do not appear to benefit from other therapies," said chief medical officer Antonio Gualberto.

“Based on these very encouraging results, we are exploring available options to advance the development of tipifarnib in this patient population as quickly as possible.”

Kura shares surged 89% in early deals to US$12.95.

View full KURA profile View Profile

Kura Oncology Timeline

Related Articles

cancer cells
December 15 2017
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 12 2017
Richard Lipscombe talked revenue generation and growth path with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use